Briefly explain how next‑generation sequencing (NGS) combined with multiplex ligation‑dependent probe amplification (MLPA) is used for a presentation.

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

NGS with MLPA for Presentation: A Combined Approach

NGS combined with MLPA represents a powerful dual-methodology approach that overcomes the technical limitations of each method alone, particularly for detecting copy number variations (CNVs) and challenging genetic regions that standard NGS cannot reliably assess.

Why Combine These Technologies?

Technical Limitations Addressed

Standard short-read NGS has significant blind spots that MLPA can fill 1:

  • Pseudogene families (e.g., CYP21A2 for congenital adrenal hyperplasia, GBA for Gaucher disease)
  • Highly homologous regions (e.g., SMN1/SMN2 for spinal muscular atrophy, HBA1/HBA2 for alpha-thalassemia)
  • Repeat expansions (e.g., FMR1 for fragile X syndrome, though this requires additional specialized techniques)
  • CNV detection accuracy - NGS can produce inaccurate CNV calls due to target sequence capture issues 2

The MLPA-NGS Hybrid Method

The innovative approach involves using MLPA PCR products to construct an NGS library, rather than traditional capillary electrophoresis 3, 2:

  • MLPA probes target specific sequences of interest
  • PCR products are indexed with adapters for NGS platforms (particularly Illumina)
  • Fragment differentiation is based on specific base composition rather than fragment length
  • Allows simultaneous analysis of up to 1000 target sequences (compared to 60 probes maximum in traditional MLPA) 4

Clinical Applications for Presentation

Carrier Screening Context

For preconception/prenatal carrier screening, MLPA serves as the required ancillary technology for technically challenging tier 3 genes 1:

Gene Challenge Why MLPA is Needed
SMN1 Homology with SMN2 qPCR or MLPA required as ancillary to NGS
CYP21A2 Pseudogene conversion MLPA detects gene conversions NGS misses
HBA1/2 High homology qPCR or MLPA needed for accurate CNV detection

Muscular Dystrophy Diagnosis

The sequential approach of MLPA followed by NGS achieves 91.4% diagnostic yield 5:

  1. First-line MLPA screening detects large deletions/duplications (75.8% of DMD mutations are deletions)
  2. NGS for MLPA-negative cases identifies point mutations, small indels, splice-site variants
  3. Combined approach identified 62/68 cases in one cohort 3, 5

Hematologic Malignancies

DigitalMLPA (NGS-based MLPA) shows 98.9% sensitivity and 97.8% specificity for ALL genetic work-up 4:

  • Detects subclonal alterations present in ≥20-30% of cells
  • Identifies whole chromosome gains/losses, intragenic deletions, fusion genes
  • Provides comprehensive genetic characterization in a single assay

Key Advantages of the Combined Approach

High-throughput capability: Multiple samples and targets analyzed simultaneously through indexed adapters 3, 2

Cost-effectiveness: MLPA is rapid and economical for initial screening, reserving comprehensive NGS for cases requiring deeper analysis 6

Complementary strengths:

  • MLPA excels at CNV detection with high precision
  • NGS captures point mutations and provides sequence-level detail
  • Together they provide complete genetic characterization

Common Pitfalls to Avoid

⚠️ Do not rely on short-read NGS alone for CNV detection - it produces inaccurate results for homologous regions and pseudogenes 1, 7

⚠️ MLPA must be performed first in the diagnostic algorithm for conditions like DMD - it captures 75-80% of mutations and is more cost-effective than starting with comprehensive NGS 5

⚠️ Reference genome choice matters - GRCh37 vs GRCh38 can affect variant calling in genes like CBS; laboratories must be aware of these discrepancies 1

⚠️ Traditional MLPA has probe limitations (maximum 60 probes) - the NGS-based MLPA variant overcomes this by allowing up to 1000 targets 4

Practical Implementation

For clinical presentations, emphasize this workflow:

  1. Initial MLPA screening for known CNVs in target genes
  2. NGS analysis for MLPA-negative cases or when point mutations suspected
  3. MLPA-NGS hybrid when high-throughput screening of multiple targets needed
  4. Confirmatory testing with orthogonal methods (Sanger sequencing, qPCR) for critical findings

The combined approach is particularly valuable when:

  • Screening for multiple genetic conditions simultaneously
  • Analyzing genes with complex architecture (pseudogenes, homology)
  • Detecting both large structural variants and point mutations
  • Managing resource-limited settings requiring cost-effective initial screening 6

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.